Develops non-invasive home tests for early warning of health abnormalities, then licenses their manufacturing and distribution to commercial partners.
20-F for FY2025, filed Apr 30, 2026
No revenue reported yet.
20-F for FY2025, filed Apr 30, 2026
Commercial partners license the products and handle sales and distribution in their territories; consumers are intended to buy the home tests over the counter, including through pharmacies and online platforms.
20-F for FY2025, filed Apr 30, 2026The Company operates under a licensing-based commercialization model pursuant to which it designs, develops, and patents medical products…View ↗
Marketing, sales, and distribution, including pricing strategy, channel development, and relationships with pharmacies, online platforms…View ↗
Each of the Company’s products — BreastCheck, FootFlow, Testic, and ThermaDerm — are designed and intended to be sold directly to consumers…View ↗
Loading...
